hNTCP‑expressing primary pig hepatocytes are a valuable tool for investigating hepatitis B virus infection and antiviral drugs.


Journal

Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 28 01 2019
accepted: 24 07 2019
pubmed: 6 9 2019
medline: 20 2 2020
entrez: 6 9 2019
Statut: ppublish

Résumé

Primary human hepatocytes (PHHs) are the 'gold standard' for investigating hepatitis B virus (HBV) infection and antiviral drugs. However, poor availability, variation between batches and ethical issues regarding PHHs limit their applications. The discovery of human sodium taurocholate co‑transporting polypeptide (hNTCP) as a functional HBV receptor has enabled the development of a surrogate model to supplement the use of PHHs. In the present study, the evolutionary distance of seven species was assessed based on single‑copy homologous genes. Based on the evolutionary distance and availability, PHHs and primary rabbit hepatocytes (PRHs) were isolated and infected with hNTCP‑recombinant lentivirus, and susceptibility to HBV infection in the two cell types was tested and compared. In addition, HBV infection efficiency of hNTCP‑expressing PPHs with pooled HBV‑positive serum and purified particles was determined. The potential use of HBV‑infected hNTCP‑expressing PPHs for drug screening was assessed. The results demonstrated that pigs and rabbits are closer to humans in the divergence tree compared with mice and rats, indicating that pigs and rabbits were more likely to facilitate the HBV post‑entry lifecycle. Following hNTCP complementation and HBV infection, PPHs and Huh7D human hepatocellular carcinoma cells, but not PRHs, exhibited increased hepatitis B surface antigen and hepatitis B e‑antigen secretion, covalently closed circular DNA formation and infectious particle secretion. hNTCP‑expressing PPHs were susceptible to infection with HBV particles purified from pooled HBV‑positive sera, but were poisoned by raw HBV‑positive sera. The use of HBV‑infected hNTCP‑expressing PPHs for viral entry inhibitor screening was revealed to be applicable and reproducible. In conclusion, hNTCP‑expressing PPHs may be valuable tool for investigating HBV infection and antiviral drugs.

Identifiants

pubmed: 31485670
doi: 10.3892/mmr.2019.10628
pmc: PMC6755163
doi:

Substances chimiques

Antiviral Agents 0
Organic Anion Transporters, Sodium-Dependent 0
Symporters 0
sodium-bile acid cotransporter 145420-23-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3820-3828

Références

Biochim Biophys Acta. 1999 Oct 8;1455(2-3):403-18
pubmed: 10571028
J Virol. 2001 Jun;75(11):5084-9
pubmed: 11333889
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Virology. 2003 May 10;309(2):339-49
pubmed: 12758180
J Virol. 2003 Sep;77(17):9511-21
pubmed: 12915565
Gastroenterology. 2005 Jul;129(1):234-45
pubmed: 16012950
J Virol. 1992 Jul;66(7):4107-16
pubmed: 1602535
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8495-9
pubmed: 1656445
Ann Epidemiol. 2009 Apr;19(4):231-4
pubmed: 19344859
Virol J. 2010 Mar 17;7:60
pubmed: 20233455
PLoS Pathog. 2010 Sep 02;6(9):e1001082
pubmed: 20824087
Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):541-50
pubmed: 20932139
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
Hua Xi Yi Ke Da Xue Xue Bao. 1990 Jun;21(2):181-4
pubmed: 2391101
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16151-6
pubmed: 24043818
J Virol Methods. 2014 Jan;195:185-93
pubmed: 24134944
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
J Virol Methods. 2014 Oct;207:29-37
pubmed: 24977316
BMC Microbiol. 2014 Dec 11;14:315
pubmed: 25495746
Aging Cell. 2015 Jun;14(3):352-65
pubmed: 25677554
PLoS Pathog. 2015 Apr 22;11(4):e1004840
pubmed: 25902143
Sci Rep. 2016 Jul 07;6:29391
pubmed: 27384014
Hepatology. 2017 Sep;66(3):703-716
pubmed: 28195359
Am J Emerg Med. 2017 Nov;35(11):1645-1652
pubmed: 28521971
Virol Sin. 2017 Dec;32(6):465-475
pubmed: 28971350
Antimicrob Agents Chemother. 1997 Aug;41(8):1715-20
pubmed: 9257747

Auteurs

Ming Zhou (M)

Shenzhen Xenotransplantation Research and Development Center, Institute of Translational Medicine, Health Science Center, Shenzhen University School of Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.

Bo Qin (B)

Clinical Laboratory Center, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China.

Xue-Song Deng (XS)

Department of Hepatobiliary Surgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.

Xiao-Li Zeng (XL)

Department of Internal Medicine, The Second People's Hospital of Futian District, Shenzhen, Guangdong 518049, P.R. China.

Ying Lu (Y)

Shenzhen Xenotransplantation Research and Development Center, Institute of Translational Medicine, Health Science Center, Shenzhen University School of Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.

Zi-Gang Huang (ZG)

Liver‑Biotechnology (Shenzhen) Co., Ltd., Shenzhen, Guangdong 518110, P.R. China.

Chun-Chen Wu (CC)

Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, P.R. China.

Li-Sha Mou (LS)

Shenzhen Xenotransplantation Research and Development Center, Institute of Translational Medicine, Health Science Center, Shenzhen University School of Medicine, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH